Table 2.

Summary of clinical trials investigating the potential use of ranolazine in heart failure.

Study	Year	Study Design	No. of Patients	Patient Cohort	Results
Murray, Colombo [36]	2014	Unblinded, non-randomised trial	109	Systolic or diastolic heart failure patients with NYHA Class II–IV	Treatment with ranolazine compared to standard heart failure therapy alone resulted in: Increased LVEF (>7 EFU, p < 0.001) Cardiovascular event rate reduction
Maier et al. [34]	2013	Prospective, randomised, double-blind, placebo-controlled proof-of-concept study	20	Patients with diastolic heart failure with preserved ejection fraction (EF > 45%)	In comparison to placebo, treatment with ranolazine in heart failure resulted in: Reduced left ventricular end-diastolic pressure (2.2 mmHg, p = 0.04) Reduction in cardiac out (0.3 l/min) and stroke volume (3.3 mL) (p = 0.04) No difference in exercise tolerance No difference in BNP levels
Morrow et al. [33]	2010	Randomised, double-blind, placebo-controlled trial	4543	Non-ST-segment elevation ACS patients	Treatment with ranolazine compared to placebo resulted in: 13% reduction in the rate of recurrent ischemia (HR 0.87; 95% CI 0.76–0.99; p = 0.03) No difference in incidence of new or worsening heart failure No difference in exercise performance No change in BNP concentration

NYHA = Ney York Heart Association; LVEF = left ventricular ejection fraction; EFU = ejection fraction units; BNP = brain natriuretic peptide; ACS = acute coronary syndrome.